GSK.L vs. CVX
GSK.L (GlaxoSmithKline plc) and CVX (Chevron Corporation) are both stocks. GSK.L operates in Drug Manufacturers - General (Healthcare), while CVX operates in Oil & Gas Integrated (Energy). Over the past 10 years, GSK.L returned 6.03%/yr vs 11.51%/yr for CVX. At a 0.18 correlation, their price movements are largely independent.
Performance
GSK.L vs. CVX - Performance Comparison
Loading charts...
Different Trading Currencies
GSK.L is traded in GBp, while CVX is traded in USD. To make them comparable, the CVX values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, GSK.L achieves a 10.61% return, which is significantly lower than CVX's 25.82% return. Over the past 10 years, GSK.L has underperformed CVX with an annualized return of 6.03%, while CVX has yielded a comparatively higher 11.51% annualized return.
GSK.L
- 1D
- 1.10%
- 1M
- 6.15%
- YTD
- 10.61%
- 6M
- 10.61%
- 1Y
- 32.87%
- 3Y*
- 17.81%
- 5Y*
- 6.60%
- 10Y*
- 6.03%
CVX
- 1D
- 0.84%
- 1M
- 2.47%
- YTD
- 25.82%
- 6M
- 26.88%
- 1Y
- 36.69%
- 3Y*
- 8.03%
- 5Y*
- 17.53%
- 10Y*
- 11.51%
GSK.L vs. CVX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 10.61% | 41.46% | -3.51% | 4.94% | -25.94% | 26.66% | -20.76% | 25.32% | 19.02% | -10.82% |
CVX Chevron Corporation | 25.82% | 2.26% | 3.06% | -17.95% | 77.30% | 47.63% | -28.13% | 10.89% | -4.40% | 1.03% |
Correlation
The correlation between GSK.L and CVX is -0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.01 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.04 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Jul 11, 2007 | 0.18 |
The correlation between GSK.L and CVX shifts across timeframes, from -0.06 (1 year) to 0.18 (all time), reflecting how their relationship changes across market environments.
Fundamentals
GSK.L:
£80.83B
CVX:
$371.80B
GSK.L:
£1.42
CVX:
$5.75
GSK.L:
13.93
CVX:
32.54
GSK.L:
0.31
CVX:
3.17
GSK.L:
2.48
CVX:
1.93
GSK.L:
4.53
CVX:
2.02
GSK.L:
£32.78B
CVX:
$185.89B
GSK.L:
£23.84B
CVX:
$47.27B
GSK.L:
£11.56B
CVX:
$40.44B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK.L vs. CVX — Risk / Return Rank
GSK.L
CVX
GSK.L vs. CVX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and Chevron Corporation (CVX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK.L | CVX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.26 | ||
| Sortino ratioReturn per unit of downside risk | -0.07 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.27 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 1.78 | 2.21 | -0.43 |
| Martin ratioReturn relative to average drawdown | 4.57 | 5.84 | -1.28 |
Loading charts...
Drawdowns
GSK.L vs. CVX - Drawdown Comparison
The maximum GSK.L drawdown since its inception was -42.39%, smaller than the maximum CVX drawdown of -52.60%. Use the drawdown chart below to compare losses from any high point for GSK.L and CVX.
Loading charts...
Drawdown Indicators
| GSK.L | CVX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.39% | -52.60% | +10.21% |
Max Drawdown (1Y)Largest decline over 1 year | -18.35% | -16.64% | -1.71% |
Max Drawdown (3Y)Largest decline over 3 years | -27.42% | -24.41% | -3.01% |
Max Drawdown (5Y)Largest decline over 5 years | -42.39% | -31.98% | -10.41% |
Max Drawdown (10Y)Largest decline over 10 years | -42.39% | -52.60% | +10.21% |
Current DrawdownCurrent decline from peak | -11.02% | -11.81% | +0.79% |
Average DrawdownAverage peak-to-trough decline | -12.78% | -11.65% | -1.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.93% | 6.29% | +0.64% |
Volatility
GSK.L vs. CVX - Volatility Comparison
The current volatility for GlaxoSmithKline plc (GSK.L) is 6.10%, while Chevron Corporation (CVX) has a volatility of 8.05%. This indicates that GSK.L experiences smaller price fluctuations and is considered to be less risky than CVX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK.L | CVX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.10% | 8.05% | -1.95% |
Volatility (6M)Calculated over the trailing 6-month period | 18.09% | 19.10% | -1.01% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.04% | 23.52% | +1.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.68% | 25.31% | -1.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.09% | 29.14% | -7.05% |
Dividends
GSK.L vs. CVX - Dividend Comparison
GSK.L's dividend yield for the trailing twelve months is around 3.38%, less than CVX's 3.73% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CVX Chevron Corporation | 3.73% | 4.49% | 4.50% | 4.05% | 3.16% | 4.52% | 6.11% | 3.95% | 4.12% | 3.45% | 3.64% | 4.76% |
GSK.L GlaxoSmithKline plc | 3.38% | 3.51% | 4.53% | 3.84% | 5.30% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% |
Financials
GSK.L vs. CVX - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Chevron Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GSK.L vs. CVX - Profitability Comparison
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
CVX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Chevron Corporation reported a gross profit of 4.55B and revenue of 47.56B. Therefore, the gross margin over that period was 9.6%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
CVX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Chevron Corporation reported an operating income of 3.24B and revenue of 47.56B, resulting in an operating margin of 6.8%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
CVX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Chevron Corporation reported a net income of 2.21B and revenue of 47.56B, resulting in a net margin of 4.7%.
Frequently Asked Questions
GSK.L and CVX have a correlation of -0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GSK.L and CVX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer